Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease.
Although several studies have documented reduced concentrations of somatostatin-like immunoreactivity (SLI) in the cerebral cortex in Alzheimer's disease, there is controversy concerning the extent and importance of these changes. We measured SLI in brains obtained post mortem from 12 patients with pathologically confirmed Alzheimer's disease and from 13 neurologically normal controls. All major cortical and subcortical regions were examined. Widespread reductions of SLI in Alzheimer's disease cerebral cortex were found, with the most profound changes seen in temporal lobe; but there also were major reductions in both the frontal and occipital cortex. There were no significant reductions in subcortical regions. Characterization of SLI by high-pressure liquid chromatography showed no significant difference in profiles between Alzheimer's disease and control frontal cortex. These results suggest that the reduction in somatostatin immunoreactivity in Alzheimer's disease may be caused by degeneration of intrinsic somatostatin cortical neurons.
D000110:Acetylcholinesterase / Q000378:metabolism; D000368:Aged; D000544:Alzheimer Disease / Q000378:metabolism*; D001479:Basal Ganglia / Q000032:analysis; D002540:Cerebral Cortex / Q000032:analysis*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D008032:Limbic System / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000032:analysis; D010455:Peptides / Q000032:analysis*; D011863:Radioimmunoassay; D013702:Temporal Lobe / Q000032:analysis
D009478:Neuropeptide Y; D010455:Peptides; C029993:somatostatin-like peptides; D000110:Acetylcholinesterase